HealthCare Global Enterprises Limited Q2 Revenue Rises 16%

HealthCare Global Enterprises Limited reported Q2 FY2027 revenue of INR 7,318 million, up 16% year-on-year, as patient volumes rose 9% and average revenue per patient increased 7%. The performance matters because it combined broad-based operating-cluster growth with a rise in EBITDA margin to 19.7%.

What did HCG report for Q2 FY2027?

HCG reported revenue of INR 7,318 million for the quarter, a 16% increase from the corresponding quarter of the previous year. Excluding the new North Bengaluru hospital, revenue growth was 14% year-on-year. Management said the growth was broad-based across its operating clusters rather than being limited to a single location.

The company attributed the increase principally to 9% growth in patient volumes and a 7% rise in average revenue per patient, or ARPP. Higher complexity oncology treatments and a favourable payer mix supported the increase in revenue per patient. These factors indicate that revenue growth reflected both more patient activity and a change in the treatment and payment mix.

Quarterly EBITDA was INR 1,425 million, including a INR 61 million loss from the North Bengaluru facility. EBITDA increased 17% year-on-year, while the margin improved to 19.7% from 19.2% in Q2 of the previous financial year. The margin movement accompanied revenue growth despite the loss from the new hospital.

How did HCG perform in the first half of FY2027?

HCG recorded consolidated revenue of INR 14,100 million in H1 FY2027, up 15% year-on-year. Patient volumes increased 9% during the first half and ARPP rose 6%, according to the earnings call. Management linked the ARPP improvement to a favourable payer mix and a larger contribution from high-end procedures, including robotic surgeries.

Adjusted EBITDA for H1 FY2027 stood at INR 2,740 million, representing 18% year-on-year growth. The adjusted EBITDA margin improved by 84 basis points to 19.7%, compared with 18.8% in H1 FY2026. HCG cited improving revenue quality and operating efficiencies as the basis for the margin expansion.

What is driving HCG's revenue and margin growth?

HCG said its operating clusters delivered broad-based growth, led by higher patient volumes. The company also reported that the revenue mix shifted towards high-complexity oncology treatments. In the first half, it specifically identified robotic surgeries among the higher-end procedures contributing to ARPP growth.

The comparison between reported quarterly revenue growth of 16% and 14% growth excluding North Bengaluru shows that the newly opened hospital added to the reported revenue increase. However, the facility also recorded a INR 61 million EBITDA loss in the quarter. This establishes that the new hospital contributed revenue while remaining a current-period cost to profitability.

HCG's prior disclosures provide context for its expansion focus. In FY2026, the company reported 15% revenue growth and 19% EBITDA growth, and outlined a target to add 1,000 beds by FY2030. Its Q1 FY2027 revenue was INR 6,951 million, up 13% year-on-year, with adjusted EBITDA margin of 19.4%. The Q2 outcome extends the reported pattern of revenue growth and margin improvement in FY2027.

What does the Q2 update mean for investors and operations?

For investors, the key operating measures were the simultaneous 9% increase in patient volumes and 7% ARPP growth in Q2. Revenue growth that comes from both activity and revenue per patient can affect the company’s reported sales mix, while the 50-basis-point margin improvement shows that EBITDA grew slightly faster than quarterly revenue.

The North Bengaluru result remains relevant to HCG's expansion economics. Its INR 61 million quarterly loss was included in EBITDA, so the company’s reported 19.7% margin already reflects the impact of that facility. The earnings call did not provide a timeline for the hospital's profitability or a separate revenue figure for it.

Management retained guidance for mid-teens revenue growth and high-teens EBITDA growth. It also identified drug-price caps as a near-term headwind. The transcript did not quantify the financial effect of the caps, so their eventual influence on revenue, treatment economics or margins was not specified. For the healthcare industry, the update highlights the importance of patient volumes, complex-procedure mix, payer mix and operating efficiency in determining hospital financial performance.

Conclusion

HCG's Q2 FY2027 update showed 16% revenue growth to INR 7,318 million and 17% EBITDA growth to INR 1,425 million. Higher patient volumes, ARPP growth and a larger contribution from high-complexity oncology treatments supported the result, while the EBITDA margin rose to 19.7% despite the North Bengaluru hospital loss.

The next points to watch are HCG's progress against its mid-teens revenue and high-teens EBITDA growth guidance, the operating trajectory of the North Bengaluru hospital, and any disclosed effect of drug-price caps. The company has also stated a target of adding 1,000 beds by FY2030, making expansion execution an important longer-term operating measure.